| Name | Zafirlukast |
| Description | Zafirlukast (ICI 204219) is an orally active leukotriene D4 receptor (LTD4) antagonist (IC50=0.6 μM). Zafirlukast has anti-asthmatic, anti-inflammatory, and antimicrobial properties and is used in the prevention and treatment of asthma. |
| In vitro | METHODS: Loucy cells were treated with THZ1 (0.8-500 nM) for 4 h. Binding was detected by LanthaScreen Eu Kinase Binding assay.
RESULTS: THZ1 showed time-dependent inhibition of CDK7 in vitro and covalent binding of intracellular CDK7. [1]
METHODS: NSCLC cell lines H1299, A549 and H292 were treated with THZ1 (10-10000 nM) for 48 h. Cell viability was measured by crystal violet assay.
RESULTS: THZ1 dose-dependently inhibited the migration and proliferation of NSCLC cells. [2] |
| In vivo | METHODS: To detect anti-tumor activity in vivo, THZ1 (10 mg/kg) was injected intravenously twice daily for 28 days into NU/NU mice bearing MYCN-amplified human NB xenografts.
RESULTS: THZ1 inhibited tumor growth in the human MYCN-amplified NB mouse model. [3]
METHODS: To detect the antitumor activity in vivo, THZ1 (10 mg/kg) was injected intraperitoneally into NSG mice bearing KYSE510 tumors twice daily for 24 days.
RESULTS: THZ1 inhibited the growth of KYSE510 xenografts and suppressed lung metastasis in the NSG mouse model. [4] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.95 mM), Sonication is recommended.
DMSO : 105 mg/mL (182.39 mM), Sonication is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | Zafirlukast | LeukotrieneReceptor | leukotriene receptor | Inhibitor | inhibit | ICI-204219 | ICI204219 |
| Inhibitors Related | Moxilubant HCl | Montelukast sodium | LTB4-IN-1 | L 674573 | Olsalazine disodium | Pirodomast | Pranlukast | Desloratadine | CGP 35949 | ABT-080 | Darbufelone mesylate | Ticolubant |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Inhibitor Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
